EUVIMEDEUVIMED entdecken
Crossref

71729 Beyond Monotherapy: Synergistic TYK2 and IL-23 Inhibition for the Effective Management of Treatment-Resistant Psoriasis

Joseph Visingardi, Bryan Sherwood, Brian Simmons

Journal of the American Academy of Dermatology · 2026-07 · 95 (1) · AB74

DOI: 10.1016/j.jaad.2026.04.308 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Academy of Dermatology, 2026-07. Verfasst von Joseph Visingardi und 2 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Visingardi, J., Sherwood, B., & Simmons, B. (2026). 71729 Beyond Monotherapy: Synergistic TYK2 and IL-23 Inhibition for the Effective Management of Treatment-Resistant Psoriasis. Journal of the American Academy of Dermatology, 95(1), AB74. https://doi.org/10.1016/j.jaad.2026.04.308

Vancouver

Visingardi J, Sherwood B, Simmons B. 71729 Beyond Monotherapy: Synergistic TYK2 and IL-23 Inhibition for the Effective Management of Treatment-Resistant Psoriasis. Journal of the American Academy of Dermatology. 2026;95(1):AB74. doi:10.1016/j.jaad.2026.04.308

BibTeX
@article{Visingardi2026,
  author = {Visingardi, Joseph and Sherwood, Bryan and Simmons, Brian},
  title = {71729 Beyond Monotherapy: Synergistic TYK2 and IL-23 Inhibition for the Effective Management of Treatment-Resistant Psoriasis},
  journal = {Journal of the American Academy of Dermatology},
  year = {2026},
  volume = {95},
  number = {1},
  pages = {AB74},
  doi = {10.1016/j.jaad.2026.04.308}
}
Kostenlos starten →